NLSDays 2022, taking place at Malmömässan on September 28-29, will offer hot topics, inspiring discussions, and not least, opportunities for the life science community to meet, mingle and create business
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
NLS News
Denmark and Sweden are the two leading life science nations of the Nordics, and both countries rank in the top-10 of most innovative countries in the world1. Coming together in
These five Nordic life science companies are at different stages of development, with different focus areas, from different Nordic countries, and they represent the different strongholds that the region possesses.
The Finnish company has signed a second clinical trial collaboration and supply agreement with MSD for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines,
Oncopeptides has announced that the Oncologic Drugs Advisory Committee (ODAC), of the FDA, has finalized the discussion on the benefit-risk profile of Pepaxto. A majority of the panel considered that
AstraZeneca and MSD’s Lynparza has been approved in China for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete
During a meeting at the US ambassador’s residence in Sweden on September 20th, collaboration on data driven life sciences and Real World Evidence’s (RWE’s) impact on Swedish life sciences was
Alligator Bioscience and Aptevo Therapeutics have announced the “may proceed” notification for the ALG.APV-527 investigational new drug application (IND). The notification allows the companies to initiate clinical trials evaluating the
The Board of NorthX Biologics has appointed the former Director General of SwedenBIO, Helena Strigård, as their new Chief Executive Officer. She will lead NorthX’s continued expansion in the development
Three members of the company’s Board, Solveig Hellebust, Jean Pierre Bizzari and Thomas Ramdahl, has decided to step down from the Board with immediate effect. Following the decisions to discontinue
Frida Lawenius, who has been Deputy Director General of SwedenBIO since January 2020, brings experience from both political influence and strategic development into her new role. ”Frida Lawenius is an
The company has become a partner of EHDEN, a private-public partnership that is building a large-scale, federated network of data sources standardized to a common data model. Lundbeck now joins
The two companies have entered a new strategic collaboration to combine Microsoft’s computational services, cloud and artificial intelligence with Novo Nordisk’s drug discovery, development and data science capabilities. Through the
The COVID-19 pandemic
Sweden’s Minister of Health and Social Affairs, Lena Hallengren, has officially inaugurated Valneva Sweden’s new COVID-19 vaccine manufacturing facility, the first and only one of its kind in Sweden. “The
Evusheld, a long-acting antibody combination, has been approved in the European Union (EU) for the treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen and who
Researchers at Karolinska Institutet are developing a coronavirus vaccine designed to be less sensitive to mutations and equipped for future strains. The vaccine showed promising results in mice in a
Two ongoing research studies funded by NordForsk are providing new knowledge about COVID-19 related to pregnancy and mental health. The Nordic countries have similar welfare systems, access to high-quality health
Bavarian Nordic has provided an update on the Phase 3 development of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate. The upcoming Phase 3 trial has been redesigned to include
Drug and device development
Nordic Nanovector has provided an update on PARADIGME, its Phase 2b trial of Betalutin in 3rd-line relapsed and anti-CD20 refractory follicular lymphoma. Following a comprehensive review and independent data evaluation
The company’s study is published in the journal Obesity, and also chosen as “Editor’s Choice” for the November issue. The aim of Empros Pharma’s study was to evaluate the effect
Cyxone has received approvals from the Medical Product Agency and the Central Ethics Committee in Poland to start a clinical Phase 2b study with its drug candidate Rabeximod, which is
AlzeCure Pharma has received new data from the clinical phase I study (multiple ascending dose, MAD) with repeated dosing of the drug candidate ACD856, which is being developed against Alzheimer’s
Alligator Bioscience has announced a poster presentation on the OPTIMIZE-1 Phase 1b/2 trial of mitazalimab in combination with modified FOLFIRINOX in first-line metastatic pancreatic cancer with the company’s lead asset
Profile
One of Nobel Laureate David Julius’ greatest joys is when people in his lab show him exciting data and make their own discoveries, and as a scientist and educator his
In a new job
Anki Malmborg Hager has extensive experience in the life sciences, including as a business developer and CEO of the Lund companies Cantargia, Diaprost, Senzagen and PainDrainer. “We’re thrilled to have
Anders Blanck has been CEO of the trade association for the research-based pharmaceutical industry in Sweden (Lif) since 2011, and before that he was deputy CEO since 2005. Blanck will
Idogen has announces that Anders Karlsson has decided to leave the company to move on to a CEO role in another Swedish biotechnology company. “It has been a privilege to
Careers
In his job as Project Director at AstraZeneca’s Pharmaceutical Development unit, Anders Holmén constantly has to be one step ahead and has to be able to see how science best
Read the latest issue of our magazine!
No 03 2022 // In the new, post-COVID-19 world of work, innovation districts are well-positioned to thrive. For this reason we have chosen to take a closer look at five Nordic innovation districts, at different development stages and with different challenges and life science offerings, but with the same goal of facilitating knowledge transfer and spurring innovation and life science growth in our region and beyond.
In addition, we present our Nordic Life Science Stars – five up-and-coming companies (one in each Nordic country), with different journeys, and goals, but all with the same passion. This issue also includes columns on cross-border strengths and the current Nordic financial challenges, a commentary about pandemic preparedness, and a careers interview with a Manager of analytical development.
This, and much more, in our latest issue – out now!
Venture Capital
Nordic Life Science asked Fredrik Dahl, co-founder at Colibri Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
Nordic Life Science asked Inka Mero, Founder and Managing Partner at Voima Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
“Start by asking what the problem is that you are trying to solve and develop the technology, team, and plan to solve that problem – not what you can do with the technology.” – Fredrik Dahl, Colibri Ventures
Upcoming events
Since its inception in 2013, NLSDays has nurtured a community of people from the world of life science, and created a unique place to do business. This annual event offers an informal
This event is scheduled as a 3 day in-person event in Leipzig, October 24-26, and a 3 day virtual event, November 2-4. This year the event will be held in
At Outsourcing in Clinical Trials and Clinical Trial Supply Nordics the pharmaceutical, biotechnology, and medical device communities need to come together and discuss strategies for operational success in clinical trials.
Both MEDICA 2022 and COMPAMED 2022 will reflect the entire medical technology value and process chains and present a comprehensive range of medical products, devices and instruments. In 2021, both
The latest research news from the Nordic region
Science Article
Scientists at deCODE genetics together with collaborators from Denmark report on the whole genome sequences of 150 thousand participants in the UK biobank in a paper published in the journal
A variant typical of the Finnish population that protects against heart diseases was identified in the FinnGen genomic study coordinated by the University of Helsinki. The risk of developing heart
Turning down the thermostat seems to make it harder for cancer cells to grow, according to a study in mice by researchers at Karolinska Institutet. The study, published in the
The Nobel Prize in Chemistry 2021 shed light on a simple, sustainable and smart molecular building tool that has had a great impact on pharmaceutical production. The Royal Swedish Academy
The European Patent Office (EPO) has honoured Hungarian-American researcher Katalin Karikó with the European Inventor Award 2022 in the category “Lifetime achievement”, for her seminal work in developing modified messenger
Dr Martin Oeggerli at Micronaut GmBH, Basel, Switzerland, is this year’s winner of the Lennart Nilsson Award. Martin Oeggerli holds a PhD in medical molecular biology. Since 2005, he works
Nordic Life Science
The latest clinical trials
The company’s study is published in the journal Obesity, and also chosen as “Editor’s Choice” for the November issue. The aim of Empros Pharma’s study was to evaluate the effect
Cyxone has received approvals from the Medical Product Agency and the Central Ethics Committee in Poland to start a clinical Phase 2b study with its drug candidate Rabeximod, which is
AlzeCure Pharma has received new data from the clinical phase I study (multiple ascending dose, MAD) with repeated dosing of the drug candidate ACD856, which is being developed against Alzheimer’s
Alligator Bioscience has announced a poster presentation on the OPTIMIZE-1 Phase 1b/2 trial of mitazalimab in combination with modified FOLFIRINOX in first-line metastatic pancreatic cancer with the company’s lead asset
The Gothenburg based company has announced that an article has been published in Neurology, from the American Academy of Neurology, describing data from the company’s IPO-001 pharmacokinetic cross-over study. In
IRLAB Therapeutics have announced that its partner Ipsen has initiated clinical studies with drug candidate mesdopetam in accordance with its development plan. These are standard clinical pharmacokinetic studies that will
BioInvent International has announced the completion of the planned dose escalation part of its Phase 1/2a trial of the anti-TNFR2 drug candidate BI-1808. Given the positive safety and tolerability profile
New research shows that ILB mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including Amyothrophic Lateral Sclerosis (ALS). TikoMed
EpiEndo Pharmaceuticals has received regulatory and ethics approval to commence a Lipopolysaccharide (LPS) challenge clinical trial with its lead molecule EP395. EP395 is an orally available macrolide or ‘Barriolide’ with
Sign up to our newsletter